Infectious Diseases (except HIV/AIDS)

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19

1. Erin K. McCreary
2. J. Ryan Bariola
3. Richard J. Wadas
4. Judith A. Shovel
5. Mary Kay Wisniewski
6. Michelle Adam
7. Debbie Albin
8. Tami Minnier
9. Mark Schmidhofer
10. Russell Meyers
11. Oscar C. Marroquin
12. Kevin Collins
13. William Garrard
14. Lindsay R. Berry
15. Scott Berry
16. Amy M. Crawford
17. Anna McGlothlin
18. Kelsey Linstrum
19. Anna Nakayama
20. Stephanie K. Montgomery
21. Graham M. Snyder
22. Donald M. Yealy
23. Derek C. Angus
24. Paula L. Kip
25. Christopher W. Seymour
26. David T. Huang
27. Kevin E. Kip

Reviewed by ScreenIT

The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series

1. Nasikarn Angkasekwinai
2. Suvimol Niyomnaitham
3. Jaturong Sewatanon
4. Supaporn Phumiamorn
5. Kasama Sukapirom
6. Sansnee Senawong
7. Zheng Quan Toh
8. Pinklow Umrod
9. Thitiporn Somporn
10. Supaporn Chumpol
11. Kanokphon Ritthitham
12. Yuparat Jantraphakorn
13. Kanjana Srisutthisamphan
14. Kulkanya Chokephaibulkit

Reviewed by ScreenIT

Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study

1. Rand A. Alattar
2. Shiema Abdalla
3. Tasneem Abdallah
4. Rashid Kazman
5. Aseelah Qadmour
6. Tawheeda Ibrahim
7. Bassem Alhariri
8. Shahd H. Shaar
9. Abeer Bajwa
10. Abeir Alimam
11. Rabia Qazi
12. Fatma Ben Abid
13. Joanne Daghfal
14. Ali Eldeeb
15. Kinda Shukri
16. Ahmed Elsayed
17. Fatima Rustom
18. Musaed Alsamawi
19. Alaaeldin Abdelmajid
20. Miguel A.P. Basulto
21. Armando A.R. Cobian
22. Mohamed Abukhattab
23. Abdullatif Alkhal
24. Muna A. Almaslamani
25. Ali S. Omrani

Reviewed by ScreenIT

Identification of susceptibility loci for adverse events following COVID-19 vaccination in the Japanese population: A web-based genome-wide association study

1. Shun Nogawa
2. Hajime Kanamori
3. Koichi Tokuda
4. Kaoru Kawafune
5. Miyuki Chijiiwa
6. Kenji Saito
7. Shoko Takahashi

Reviewed by ScreenIT

COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme

1. Clare L. Fasching
2. Venice Servellita
3. Bridget McKay
4. Vaishnavi Nagesh
5. James P. Broughton
6. Alicia Sotomayor-Gonzalez
7. Baolin Wang
8. Noah Brazer
9. Kevin Reyes
10. Jessica Streithorst
11. Rachel N. Deraney
12. Emma Stanfield
13. Carley G. Hendriks
14. Becky Fung
15. Steve Miller
16. Jesus Ching
17. Janice S. Chen
18. Charles Y. Chiu

Reviewed by ScreenIT

SARS-CoV-2 Delta variant saliva viral load is 15-fold higher than wild-type strains

1. Kenichi Imai
2. Ryo Ikeno
3. Hajime Tanaka
4. Norio Takada

Reviewed by ScreenIT

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

1. Francisco Hernández-Bernal
2. Maria C. Ricardo-Cobas
3. Yenima Martín-Bauta
4. Zadis Navarro-Rodríguez
5. Marjoris Piñera-Martínez
6. Joel Quintana-Guerra
7. Karen Urrutia-Pérez
8. Klaudia Urrutia-Pérez
9. Cristina O. Chávez-Chong
10. Jorge L. Azor-Hernández
11. José L. Rodríguez-Reinoso
12. Leonardo Lobaina-Lambert
13. Elizabeth Colina-Ávila
14. Jacqueline Bizet-Almeida
15. Jeniffer Rodríguez-Nuviola
16. Sergio del Valle-Piñera
17. Mayara Ramírez-Domínguez
18. Elisangela Tablada-Ferreiro
19. Marel Alonso-Valdés
20. Gilda Lemos-Pérez
21. Gerardo E. Guillén-Nieto
22. Ariel Palenzuela-Díaz
23. Enrique Noa-Romero
24. Miladys Limonta-Fernández
25. Juan M. Fernández-Ávila
26. Nabil A. Ali-Mros
27. Lianne del Toro-Lahera
28. Rossana Remedios-Reyes
29. Marta Ayala-Ávila
30. Verena L. Muzio-González

Reviewed by ScreenIT

A modelling approach to estimate the transmissibility of SARS-CoV-2 during periods of high, low, and zero case incidence

1. Nick Golding
2. David J Price
3. Gerard Ryan
4. Jodie McVernon
5. James M McCaw
6. Freya M Shearer

• Curated by eLife

  Evaluation Summary:

  This paper is interesting, timely and important because it presents a way to understand the transmission potential of a virus even when there are very few local cases. This has a high public health communication and preparedness value. The paper is clearly written, and the results fit with the known epidemiology of the various outbreaks that occurred in Australia in 2020. The paper is likely to be of broad interest within and outside the field of epidemiological modelling.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #1 and Reviewer #2 agreed to share their name with the authors.)

Reviewed by eLife, ScreenIT

Development and Implementation of Dried Blood Spot-Based COVID-19 Serological Assays for Epidemiologic Studies

1. Marcus P. Wong
2. Michelle A. Meas
3. Cameron Adams
4. Samantha Hernandez
5. Valerie Green
6. Magelda Montoya
7. Brett M. Hirsch
8. Mary Horton
9. Hong L. Quach
10. Diana L. Quach
11. Xiaorong Shao
12. Indro Fedrigo
13. Alexandria Zermeno
14. Julia Huffaker
15. Raymond Montes
16. Alicia Madden
17. Sherri Cyrus
18. David McDowell
19. Phillip Williamson
20. Paul Contestable
21. Mars Stone
22. Josefina Coloma
23. Michael P. Busch
24. Lisa F. Barcellos
25. Eva Harris

Reviewed by ScreenIT

Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis

1. Yang Liu
2. Carl A.B. Pearson
3. Frank G. Sandmann
4. Rosanna C. Barnard
5. Jong-Hoon Kim
6. Stefan Flasche
7. Mark Jit
8. Kaja Abbas

Reviewed by ScreenIT